Superdrol and TRT: separating fact from fitness influencer fiction

What did @coach.agz actually say?

The core claim here is blunt: injectable Superdrol is not safer than oral Superdrol, and may actually be more dangerous. The creator argues that because Superdrol's toxicity comes from its C17-alpha alkylation at the molecular level, not from being swallowed, suspending that same molecule in oil does nothing to reduce liver stress. He also claims that injection bypasses first-pass metabolism, meaning the parent compound hits circulation immediately and potentially harder. He recommends a two-to-three week window for advanced users and layers on a list of protective supplements: TUDCA, NAC, omega-3s, and telmisartan, alongside lab monitoring and strict alcohol avoidance.

Does the science back this up?

On the core pharmacology, he's largely right. The hepatotoxicity of C17-alpha alkylated androgens is well-documented and tied specifically to that chemical modification, not the route of administration. Yoshida et al. (2006, Journal of Clinical Gastroenterology) documented severe cholestatic liver injury from C17-AA androgens, and that mechanism does not change when the molecule is injected. The first-pass bypass argument is also pharmacologically sound. Oral C17-AA steroids still undergo significant hepatic extraction on the first pass; injection avoids that initial dilution, meaning higher peak plasma concentrations for the same dose. Kopera (1985, Acta Endocrinologica) outlined these kinetic differences in androgenic steroids. His points about lipid dysregulation and blood pressure elevation are supported by Baggish et al. (2017, Circulation), which found significant HDL suppression and left ventricular changes in long-term androgen users, with short-cycle oral C17-AA compounds being among the most acutely disruptive to lipid panels.

What did they get wrong or right?

He gets the fundamental chemistry right, and that deserves credit because this is genuinely where a lot of fitness misinformation lives. The claim that injectable equals safer is widespread, and calling it out directly is accurate. However, his supplement stack deserves scrutiny. TUDCA has legitimate hepatoprotective data in bile acid metabolism (Beuers et al., 2010, Hepatology), and NAC has antioxidant support in liver stress contexts. But framing these as meaningful mitigation for a compound this hepatotoxic is a stretch. They reduce some biomarker noise; they do not make Superdrol safe. The claim that ALT and AST can "skyrocket" is accurate but understated. Elevations can reach 10 to 20 times the upper limit of normal with C17-AA androgens, which crosses into clinically serious territory, not just a lab anomaly. He also uses the term "methastarum," which appears to be a verbal approximation of methandrostenolone or methyldrostanolone. Superdrol is methyldrostanolone, not methandrostenolone (Dianabol). That distinction matters if someone is actually researching the compound.

What should you actually know?

Superdrol, chemically methyldrostanolone, is one of the most hepatotoxic anabolic steroids available. It is not approved by the FDA for any therapeutic use and has been banned as a dietary supplement ingredient since 2012. The injectable form exists in gray-market and underground lab products and carries no additional safety margin over oral. Cases of acute liver failure have been attributed to short-cycle use of C17-AA androgens in otherwise healthy individuals (Kafrouni et al., 2007, Annals of Pharmacotherapy). The protective supplement stack the creator mentions has some biological rationale but has not been tested in human trials specifically against Superdrol-induced liver injury. Anyone monitoring their own labs while using this compound is doing the minimum responsible thing, but labs normalize after a cycle ends and do not reflect accumulated structural damage. Telmisartan is an angiotensin receptor blocker used clinically for hypertension and is a prescription drug. Recommending it as a cycle adjunct without prescriber involvement is outside the scope of fitness coaching.

The bottom line on injectable versus oral Superdrol

The creator's central pharmacological argument holds up. Route of administration does not neutralize C17-alpha alkylation toxicity, and the first-pass bypass argument for injection is mechanistically valid. Where the video gets murkier is in framing this as something "advanced users" can manage with supplements and lab work. The research on C17-AA androgen hepatotoxicity does not support a reliably safe window, even with mitigation. The two-to-three week framing sounds controlled; the literature on idiosyncratic drug-induced liver injury suggests individual susceptibility varies widely and unpredictably (Chalasani et al., 2014, Hepatology). That variability is the part this video glosses over.